Introduction {#s001}
============

Worldwide, lung cancer remains the leading cause of cancer morbidity and mortality for men and women, with 2.1 million new lung cancer cases (11.6% of the total cancer cases) and 1.8 million deaths (18.4% of the total cancer deaths) predicted in 2018, according to GLOBOCAN 2018 produced by the International Agency for Research on Cancer (Bray *et al.*, [@B5]). It is widely known that smoking is the most universal and primary risk factor for lung cancer. However, smoking cannot clarify all etiologies of lung cancer, which suggested that other environmental risk factors or genetic risk factors might play critical roles in lung carcinogenesis.

Human genome sequencing has found that protein-coding genes accounted for 3% of human DNA; however, more than 80% of our genome are actively transcribed into a miscellaneous group of RNA transcripts without potentiality for protein coding (Djebali *et al.*, [@B8]; ENCODE Project Consortium, [@B9]; Martens-Uzunova *et al.*, [@B18]). These transcripts were called noncoding RNAs (ncRNAs), including long noncoding RNAs (lncRNAs) and small noncoding RNAs such as microRNAs, short interfering RNAs, PIWI-interacting RNAs, and so forth.

LncRNAs are a heterogeneous group of noncoding transcripts, with more than 200 nucleotide (nt) in length, participating in a series of biological processes such as regulating chromatin dynamics, gene expression, growth, differentiation, and development (Esteller, [@B10]; Bhan *et al.*, [@B3]). Previous studies have indicated that lncRNAs are widely correlated to multiple cancers, the mutation and abnormal expression of which are closely associated with tumorigenesis, metastasis, and tumor stage (Kornfeld and Bruning, [@B15]; Vitiello *et al.*, [@B27]; Bartonicek *et al.*, [@B2]). Abnormal expression of lncRNAs is presented in many cancers, which can be detected in urine and/or circulating blood; therefore, lncRNAs can act as a new class of potential biomarkers and therapeutic targets for cancer, including lung cancer (Brunner *et al.*, [@B6]; Yan *et al.*, [@B35]; Shi *et al.*, [@B25]; Bhan *et al.*, [@B3]).

Previous genome-wide association studies (GWAS) and molecular epidemiological studies have explored the underlying associations between single nucleotide polymorphisms (SNPs) in ncRNAs and disease risk. There is substantial evidence to support the association between SNPs in ncRNA and cancer risk.

Prostate cancer-associated transcript 1 (*PCAT1*) is a newly discovered lncRNA located in 8q24.21, which is first demonstrated to promote deterioration and progression of prostate cancer (Prensner *et al.*, [@B21]). Previous studies have shown that lncRNA-*PCAT1* plays key roles in multiple cancers, including lung cancer, by distinct mechanisms (Prensner *et al.*, [@B20]; Zhao *et al.*, [@B40]; Wen *et al.*, [@B30]; Bi *et al.*, [@B4]; Qiao *et al.*, [@B22], [@B23]; Ren *et al.*, [@B24]; Xu *et al.*, [@B33]; Zhang *et al.*, [@B37], [@B38]; Huang *et al.*, [@B13]; Li *et al.*, [@B16]). Further, lncRNA-*PCAT1* has been reported to predict a poor prognosis in many malignant tumors (Ge *et al.*, [@B11]; Shi *et al.*, [@B26]; Yan *et al.*, [@B34]; Cui *et al.*, [@B7]; Zhang *et al.*, [@B39]). In addition, some researchers have conducted some studies to explore associations between genetic variation in lncRNA-*PCAT1* and cancer susceptibility in the past few years. In the study from Yuan *et al.* ([@B36]), they selected four tagging SNPs (tagSNPs) and found that rs1902432 was a new susceptibility locus for prostate cancer in a Chinese population. A study in blabber cancer patients showed that rs710886 was an expression quantitative trait locos (eQTL) for lncRNA-*PCAT1* and may be a potential biomarker for the risk of bladder cancer (Lin *et al.*, [@B17]). There were also researchers who explored the association between polymorphisms on lncRNA-*PCAT1* and gastric cancer risk. They selected rs1026411 and rs12543663 in lncRNA-*PCAT1* and their results suggested that genetic variants in the two loci had no significant association with gastric cancer risk (He *et al.*, [@B12]).

Our previous GWAS results suggested a significant association between rs1026411 and rs12543663 polymorphisms and lung cancer risk; however, the result was based on a smaller sample size. Previous studies had indicated that rs710886 and rs16901904 were tagSNPs of lncRNA-*PCAT1* and rs710886 may be an eQTL for lncRNA-*PCAT1*. In this study, we took into account sample size and previous studies about genetic variants in lncRNA-*PCAT1* and cancer risk and chose four SNPs in lncRNA-*PCAT1* (rs1026411, rs12543663, rs710886, and rs16901904) to investigate the association between genetic variants in lncRNA-*PCAT1* and susceptibility to lung cancer. We hypothesized that these four SNPs may alter the risk of lung cancer. Therefore, we conducted a hospital-based case--control study in Shenyang, China to verify our hypothesis. Meanwhile, we also explored gene--environmental interactions.

Materials and Methods {#s002}
=====================

Study subjects {#s003}
--------------

The study was a hospital-based case--control study conducted in Shenyang city, located in northeastern China and approved by the Institutional Review Board of China Medical University. All included study subjects were unrelated Han Chinese and were divided into two groups including 468 lung cancer patients as case group and 561 cancer-free subjects as control group. Cases were chosen from several distinct hospitals in Shenyang. The inclusion criteria of the case group were as follows: (1) Cases were newly diagnosed by experienced doctors and examined by histopathological confirmation; (2) patients did not have a history of previous cancer and metastasized cancer; (3) patients had never received radiotherapy or chemotherapy; and (4) cases had ability to accept a 1.5-h interview. The control group was chosen from the physical examination centers of the hospitals just mentioned during the same period, and meanwhile, they should not have neoplasm and respiratory disease. All participants were requested to provide basic information and smoking exposure information from the moment that they were admitted to hospital and denoted 10 mL of venous blood, after signing the informed consent. The subjects who smoked more than 100 cigarettes in their lifetime were defined as smokers, and the rest were classified as nonsmokers. Besides, the control group was matched to the case group in terms of age (±5) and gender.

SNP genotyping {#s004}
--------------

The phenol-chloroform method was used to isolate DNA samples from all the study subjects\' venous blood samples. We selected four SNPs in lncRNA-*PCAT1*, the minimum allele frequencies of which were greater than 0.05 in the Han Chinese population. Genotyping of the SNPs was conducted by using an Applied Biosystems 7500 FAST Real-Time PCR System (Foster City, CA) using Taqman^®^ allelic discrimination (Applied Biosystems, Foster City, CA).

Statistical analysis {#s005}
--------------------

All statistical analyses were conducted by using IBM SPSS Statistics 22 software. Student\'s *t*-test and χ^2^ test were used to compare the differences in basic information (age, gender, and smoking status) and genotype distributions among case group and control group. The goodness-of-fit χ^2^ test was used to calculate Hardy--Weinberg\'s equilibrium (HWE) for SNPs in the control group. Unconditional logistic regression analysis was performed to obtain the odds ratios (ORs) and their 95% confidence intervals (CIs), which can illustrate the associations between SNPs and lung cancer risk. Crossover analysis was conducted to initially assess the interaction between four SNPs and smoking status. The further exploration of gene--environment interactions was analyzed by multiplicative interaction and the additive model. Multiplicative interaction was conducted by unconditional logistic regression, which can acquire the ORs and their 95% CIs. All ORs were adjusted by gender, age, and smoking status. The addictive interaction was evaluated through the following indicators: relative excess risk due to interaction (RERI), attributable proportion due to interaction (AP), and synergy index (S) according to the report of Andersson *et al.* ([@B1]). All tests were two sided, and *p* \< 0.05 was considered statistically significant.

Results {#s006}
=======

Subject characteristics {#s007}
-----------------------

The study included a total of 1029 study subjects, whose basic information is shown in [Table 1](#T1){ref-type="table"}. There were 561 cancer-free subjects in the control group, the average age of which was 58.44 ± 14.55 (mean ± standard deviation \[SD\]). The case group was composed of 468 lung cancer patients, including 243 lung adenocarcinoma cases, 155 squamous cell carcinoma cases, and 61 small-cell lung cancer cases. The mean age of cases was 59.69 ± 10.80 (mean ± SD). The results of the Student\'s *t*-test and χ^2^ test for age suggested that there was no significant difference between case and control groups (*p* = 0.114 and *p* = 0.273, respectively). Similarly, there was no statistically significant differences in gender distribution between the two groups (*p* = 0.913). However, the distribution of smoking status in the two groups exhibited a significant difference and the smoking rate in the case group was significantly higher than that in the control group (*p* = 0.000). The results of HWE are shown in [Supplementary Table S1](#SD1){ref-type="supplementary-material"}. The genotype frequency distributions of these SNPs in control group were in agreement with HWE (χ^2^ = 0.185, *p* = 0.667 for rs1026411; χ^2^ = 0.187, *p* = 0.665 for rs12543663; χ^2^ = 0.202, *p* = 0.653 for rs710886; and χ^2^ = 0.237, *p* = 0.627 for rs16901904).

###### 

Distribution of Demographic Variables in Lung Cancer Case and Control Groups

                                *Case (%) (*n* = 468)*   *Control (%) (*n* = 561)*   p
  ----------------------------- ------------------------ --------------------------- -------
  Age (mean ± SD)               59.69 ± 10.80            58.44 ± 14.55               0.114
  Age                                                                                
   ≤59                          217 (46.4)               241 (43.0)                  0.273
   \>59                         251 (53.6)               320 (57.0)                   
  Gender                                                                             
   Male                         242 (51.7)               292 (52.0)                  0.913
   Female                       226 (48.3)               269 (48.0)                   
  Smoking exposure                                                                   
   Never                        231 (49.4)               425 (75.8)                  0.000
   Ever                         237 (50.6)               136 (24.2)                   
  Histology                                                                          
   Non-small cell lung cancer   407 (87.0)                                            
   Lung adenocarcinoma          243 (51.9)                                            
   Squamous cell carcinoma      155 (33.1)                                            
   Small cell lung cancer       61 (13.0)                                             
   Other                        9 (1.9)                                               

SD, standard deviation.

Genotype distribution of SNPs and their associations with lung cancer susceptibility {#s008}
------------------------------------------------------------------------------------

The associations of polymorphisms in lncRNA-*PCAT1* with susceptibility to lung cancer and non-small cell lung cancer are shown in [Table 2](#T2){ref-type="table"}. No statistically significant associations were found between four SNPs and lung cancer risk in all models. However, we found that genetic variants in rs1026411 and rs710886 had significant associations with susceptibility to non-small cell lung cancer (AG vs. GG: OR^a^ = 0.701, 95% CI = 0.520--0.946, *p*\* = 0.020 and AA+AG vs. GG: OR^a^ = 0.711, 95% CI = 0.538--0.940, *p*\* = 0.017 for rs1026411; CT vs. TT: OR^a^ = 0.723, 95% CI = 0.525--0.995, *p*\* = 0.047 and CC+CT vs. TT: OR^a^ = 0.729, 95% CI = 0.541--0.982, *p*\* = 0.038 for rs710886). In addition, we failed to find a significant association between polymorphisms in rs12543663 and rs16901904 and the risk of lung cancer and non-small cell lung cancer. [Table 3](#T3){ref-type="table"} described the results of associations between polymorphisms in lncRNA-*PCAT1* and susceptibility to the subtypes of lung cancer, including lung adenocarcinoma and squamous cell carcinoma. We found that polymorphisms in rs1026411 had a significant association with lung adenocarcinoma risk (AG vs. GG: OR^a^ = 0.663, 95% CI = 0.470--0.936, *p*\* = 0.019 and AA+AG vs. GG: OR^a^ = 0.685, 95% CI = 0.497--0.943, *p*\* = 0.020). In squamous cell carcinoma, CC or CT genotype of rs710886 had a significantly decreased risk compared with TT genotype carrier (OR^a^ = 0.638, 95% CI = 0.416--0.980, *p*\* = 0.040). Besides, polymorphisms in rs16901904 also showed significant results in this subgroup. In comparison with the TT genotype carrier, the risk of squamous cell carcinoma significantly increased in the CC genotype (OR^a^ = 2.582, 95% CI = 1.078--6.186, *p*\* = 0.033); meanwhile, the recessive model of rs16901904 also presented significant results (OR^a^ = 2.381, 95% CI = 1.009--5.620, *p*\* = 0.048).

###### 

Association Between Polymorphisms in the Four Single Nucleotide Polymorphisms and Risk of Lung Cancer and Nonsmall Cell Lung Cancer

                                            *Lung cancer*   *Non-small cell lung cancer*                                               
  ------------ -------------- ------------- --------------- ------------------------------ ------- ------------ ---------------------- -------
  rs1026411    GG             196 (34.9)    184 (39.3)      1.00 (Ref)                             168 (41.3)   1.00 (Ref)              
               AG             267 (47.6)    204 (43.6)      0.761 (0.569--1.018)           0.066   171 (42.0)   0.701 (0.520--0.946)   0.020
               AA             98 (17.5)     80 (17.1)       0.776 (0.531--1.136)           0.192   68 (16.7)    0.738 (0.498--1.093)   0.130
               AA+AG vs. GG                                 0.765 (0.583--1.005)           0.054                0.711 (0.538--0.940)   0.017
               AA vs. GG+AG                                 0.904 (0.640--1.275)           0.564                0.895 (0.626--1.280)   0.544
               G allele       659 (58.7)    572 (61.1)      1.00 (Ref)                             507 (62.3)   1.00 (Ref)              
               A allele       463 (41.3)    364 (38.9)      0.906 (0.759--1.081)           0.273   307 (37.7)   0.862 (0.716--1.037)   0.115
  rs12543663   AA             472 (84.1)    394 (84.2)      1.00 (Ref)                             342 (84.0)   1.00 (Ref)              
               AC             86 (15.3)     70 (15.0)       1.039 (0.720--1.498)           0.838   61 (15.0)    1.033 (0.708--1.509)   0.865
               CC             3 (0.5)       4 (0.9)         1.369 (0.267--7.010)           0.707   4 (1.0)      1.546 (0.305--7.840)   0.599
               AC+CC vs. AA                                 1.051 (0.734--1.505)           0.787                1.052 (0.726--1.525)   0.788
               CC vs. AA+AC                                 1.361 (0.266--6.962)           0.712                1.538 (0.304--7.792)   0.603
               A              1030 (91.8)   858 (91.7)      1.00 (Ref)                             745 (91.5)   1.00 (Ref)              
               C              92 (8.2)      78 (8.3)        1.018 (0.743--1.395)           0.913   69 (8.5)     1.037 (0.748--1.437)   0.828
  rs710886     TT             150 (26.7)    140 (29.9)      1.00 (Ref)                             129 (31.7)   1.00 (Ref)              
               CT             275 (49.0)    216 (46.2)      0.785 (0.574--1.072)           0.127   184 (45.2)   0.723 (0.525--0.995)   0.047
               CC             136 (24.2)    112 (23.9)      0.801 (0.557--1.153)           0.232   94 (23.1)    0.740 (0.509--1.077)   0.116
               CC+CT vs. TT                                 0.790 (0.590--1.058)           0.114                0.729 (0.541--0.982)   0.038
               CC vs. TT+CT                                 0.934 (0.688--1.268)           0.662                0.906 (0.659--1.245)   0.542
               T              575 (51.2)    496 (53.0)      1.00 (Ref)                             442 (54.3)   1.00 (Ref)              
               C              547 (48.8)    440 (47.0)      0.933 (0.784--1.109)           0.430   372 (45.7)   0.885 (0.738--1.060)   0.184
  rs16901904   TT             364 (64.9)    294 (62.8)      1.00 (Ref)                             251 (61.7)   1.00 (Ref)              
               CT             178 (31.7)    151 (32.3)      1.124 (0.847--1.493)           0.418   134 (32.9)   1.155 (0.862--1.547)   0.336
               CC             19 (3.4)      23 (4.9)        1.515 (0.772--2.972)           0.227   22 (5.4)     1.705 (0.866--3.358)   0.123
               CC+CT vs. TT                                 1.163 (0.885--1.527)           0.279                1.208 (0.913--1.600)   0.186
               CC vs. TT+CT                                 1.457 (0.748--2.839)           0.268                1.625 (0.831--3.176)   0.156
               T              906 (80.7)    739 (79.0)      1.00 (Ref)                             636 (78.1)   1.00 (Ref)              
               C              216 (19.3)    197 (21.0)      1.118 (0.901--1.388)           0.311   178 (21.9)   1.174 (0.939--1.467)   0.158

OR adjusted by age, gender, and smoking.

*p* adjusted by age, gender, and smoking.

CI, confidence interval; OR, odds ratio; Ref, reference.

###### 

Association Between Polymorphisms in the Four Single Nucleotide Polymorphisms and Risk of Lung Adenocarcinoma and Squamous Cell Lung Cancer

                                            *Lung adenocarcinoma*   *Squamous cell carcinoma*                                                
  ------------ -------------- ------------- ----------------------- --------------------------- ------- ------------ ----------------------- -------
  rs1026411    GG             196 (34.9)    104 (42.8)              1.00 (Ref)                          62 (40.0)    1.00 (Ref)               
               AG             267 (47.6)    98 (40.3)               0.663 (0.470--0.936)        0.019   67 (43.2)    0.678 (0.437--1.051)    0.082
               AA             98 (17.5)     41 (16.9)               0.744 (0.474--1.166)        0.197   26 (16.8)    0.698 (0.392--1.243)    0.222
               AA+AG vs. GG                                         0.685 (0.497--0.943)        0.020                0.684 (0.454--1.029)    0.069
               AA vs. GG+AG                                         0.927 (0.614--1.401)        0.720                0.867 (0.513--1.465)    0.594
               G allele       659 (58.7)    306 (63.0)              1.00 (Ref)                          191 (61.6)   1.00 (Ref)               
               A allele       463 (41.3)    180 (37.0)              0.837 (0.672--1.042)        0.112   119 (38.4)   0.887 (0.685--1.148)    0.361
  rs12543663   AA             472 (84.1)    203 (83.5)              1.00 (Ref)                          133 (85.8)   1.00 (Ref)               
               AC             86 (15.3)     38 (15.6)               1.062 (0.689--1.635)        0.786   20 (12.9)    0.881 (0.494--1.572)    0.669
               CC             3 (0.5)       2 (0.8)                 1.146 (0.160--8.205)        0.892   2 (1.3)      2.640 (0.351--19.858)   0.346
               AC+CC vs. AA                                         1.065 (0.697--1.628)        0.772                0.942 (0.539--1.646)    0.833
               CC vs. AA+AC                                         1.136 (0.159--8.120)        0.899                2.688 (0.358--20.202)   0.337
               A              1030 (91.8)   444 (91.4)              1.00 (Ref)                          286 (92.3)   1.00 (Ref)               
               C              92 (8.2)      42 (8.6)                1.059 (0.723--1.551)        0.768   24 (7.7)     0.939 (0.588--1.500)    0.794
  rs710886     TT             150 (26.7)    75 (30.9)               1.00 (Ref)                          52 (33.5)    1.00 (Ref)               
               CT             275 (49.0)    111 (45.7)              0.744 (0.514--1.076)        0.116   68 (43.9)    0.645 (0.407--1.023)    0.063
               CC             136 (24.2)    57 (23.5)               0.787 (0.511--1.212)        0.277   35 (22.6)    0.624 (0.362--1.077)    0.090
               CC+CT vs. TT                                         0.758 (0.537--1.070)        0.115                0.638 (0.416--0.980)    0.040
               CC vs. TT+CT                                         0.948 (0.658--1.367)        0.775                0.817 (0.511--1.307)    0.399
               T              575 (51.2)    261 (53.7)              1.00 (Ref)                          172 (55.5)   1.00 (Ref)               
               C              547 (48.8)    225 (46.3)              0.906 (0.732--1.122)        0.365   138 (44.5)   0.843 (0.655--1.086)    0.186
  rs16901904   TT             364 (64.9)    153 (63.0)              1.00 (Ref)                          93 (60.0)    1.00 (Ref)               
               CT             178 (31.7)    81 (33.3)               1.106 (0.791--1.548)        0.555   50 (32.3)    1.268 (0.824--1.951)    0.281
               CC             19 (3.4)      9 (3.7)                 1.214 (0.515--2.862)        0.657   12 (7.7)     2.582 (1.078--6.186)    0.033
               CC+CT vs. TT                                         1.116 (0.807--1.544)        0.507                1.400 (0.931--2.106)    0.106
               CC vs. TT+CT                                         1.174 (0.502--2.746)        0.711                2.381 (1.009--5.620)    0.048
               T              906 (80.7)    387 (79.6)              1.00 (Ref)                          236 (76.1)   1.00 (Ref)               
               C              216 (19.3)    99 (20.4)               1.073 (0.822--1.400)        0.604   74 (23.9)    1.315 (0.974--1.776)    0.073

OR adjusted by age, gender, and smoking.

*p* adjusted by age, gender, and smoking.

Interaction between four SNPs and smoking status {#s009}
------------------------------------------------

[Table 4](#T4){ref-type="table"} presented the crossover analysis results of four SNPs and smoking status to investigate the gene--environmental interaction. We selected non-smokers with a protective genotype of four SNPs (AA+AG genotype of rs1026411, AA genotype of rs12543663, CC+CT genotype of rs710886, and TT genotype of rs16901904) as the reference group, respectively. The results of the crossover analysis showed that smokers with both protective and dangerous genotypes significantly increased the risk of lung cancer and nonsmall cell lung cancer compared with nonsmokers with protective genotypes. These results indicated that there might be gene--environmental interactions, for the reason that we used the additive model and the multiplicative model to further investigate the gene--environmental interaction; the results are presented in [Table 5](#T5){ref-type="table"} and [6](#T6){ref-type="table"}. We did not find significant results of the gene--environmental interaction on both the additive and multiplicative scales.

###### 

Crossover Analysis of Interaction Between Risk Genotypes of Four Single Nucleotide Polymorphisms and Smoking Exposure in Lung Cancer and Nonsmall Cell Lung Cancer

                                                 *Lung cancer*            *Non-small cell lung cancer*                                                     
  ------------ ------- ------------ ------------ ------------------------ ------------------------------ ------------ ----------------------- ------------ ---
  rs1026411    AA+AG   Never        272 (48.5)   137 (29.3)               1.00 (Ref)                                  122 (30.0)              1.00 (Ref)    
  GG           Never   153 (27.3)   94 (20.1)    1.300 (0.924--1.828)     0.132                          89 (21.9)    1.369 (0.965--1.942)    0.079        
  AA+AG        Ever    93 (16.6)    147 (31.4)   7.783 (4.949--12.238)    0.000                          117 (28.7)   6.731 (4.219--10.740)   0.000        
  GG           Ever    43 (7.7)     90 (19.2)    10.258 (6.103--17.240)   0.000                          79 (19.4)    9.935 (5.830--16.929)   0.000        
  rs12543663   AA      Never        353 (62.9)   191 (40.8)               1.00 (Ref)                                  175 (43.0)              1.00 (Ref)    
  CC+AC        Never   72 (12.8)    40 (8.5)     1.024 (0.661--1.588)     0.915                          36 (8.8)     1.006 (0.639--1.583)    0.979        
  AA           Ever    119 (21.2)   203 (43.4)   7.586 (5.017--11.471)    0.000                          167 (41.0)   6.626 (4.337--10.123)   0.000        
  CC+AC        Ever    17 (3.0)     34 (7.3)     8.406 (4.262--16.577)    0.000                          29 (7.1)     7.649 (3.803--15.387)   0.000        
  rs710886     CC+CT   Never        310 (55.3)   161 (34.4)               1.00 (Ref)                                  145 (35.6)              1.00 (Ref)    
  TT           Never   115 (20.5)   70 (15.0)    1.290 (0.894--1.862)     0.174                          66 (16.2)    1.343 (0.923--1.956)    0.123        
  CC+CT        Ever    101 (18.0)   167 (35.7)   7.897 (5.099--12.232)    0.000                          133 (32.7)   6.754 (4.306--10.596)   0.000        
  TT           Ever    35 (6.2)     70 (15.0)    9.677 (5.608--16.698)    0.000                          63 (15.5)    9.618 (5.502--16.813)   0.000        
  rs16901904   TT      Never        270 (48.1)   144 (30.8)               1.00 (Ref)                                  130 (31.9)              1.00 (Ref)    
  CC+CT        Never   155 (27.6)   87 (18.6)    1.085 (0.770--1.530)     0.640                          81 (19.9)    1.104 (0.776--1.570)    0.584        
  TT           Ever    94 (16.8)    150 (32.1)   7.221 (4.619--11.287)    0.000                          121 (29.7)   6.218 (3.924--9.853)    0.000        
  CC+CT        Ever    42 (7.5)     87 (18.6)    9.467 (5.634--15.906)    0.000                          75 (18.4)    8.827 (5.185--15.029)   0.000        

OR adjusted by age and gender.

*p* adjusted by age and gender.

###### 

Addictive Interaction Between Four Single Nucleotide Polymorphisms in Prostate Cancer-Associated Transcript 1 and Smoking Exposure in Lung Cancer and Nonsmall Cell Lung Cancer

                       *Lung cancer*     *Nonsmall cell lung cancer*                     
  ------------ ------- ----------------- ----------------------------- ----------------- -----------------
  rs1026411    RERI    0.797             −0.947 to 2.542               0.994             −0.741 to 2.730
  AP           0.192   −0.173 to 0.556   0.243                         −0.109 to 0.594   
  S            1.338   0.724 to 2.475    1.473                         0.772 to 2.811    
  rs12543663   RERI    0.517             −1.786 to 2.820               0.602             −1.602 to 2.805
  AP           0.140   −0.410 to 0.689   0.175                         −0.371 to 0.721   
  S            1.237   0.510 to 3.003    1.327                         0.512 to 3.439    
  rs710886     RERI    0.495             −1.291 to 2.281               0.806             −0.982 to 2.594
  AP           0.129   −0.293 to 0.550   0.209                         −0.184 to 0.602   
  S            1.210   0.622 to 2.354    1.395                         0.694 to 2.803    
  rs16901904   RERI    0.839             −0.809 to 2.488               0.950             −0.652 to 2.552
  AP           0.216   −0.145 to 0.577   0.256                         −0.099 to 0.611   
  S            1.411   0.736 to 2.703    1.540                         0.766 to 3.098    

AP, attributable proportion due to interaction; RERI, relative excess risk due to interaction; S, synergy index.

###### 

Multiplicative Interaction Between Four Single Nucleotide Polymorphisms in Prostate Cancer-Associated Transcript 1 and Smoking Exposure in Lung Cancer and Nonsmall Cell Lung Cancer

                              *Lung cancer*           *Nonsmall cell lung cancer*                           
  --------------------------- ----------------------- ----------------------------- ----------------------- -------
  rs1026411 (GG vs. AA+AG)    1.300 (0.924--1.828)    0.132                         1.369 (0.965--1.942)    0.079
  Smoking exposure            7.783 (4.949--12.238)   0.000                         6.731 (4.219--10.740)   0.000
  Interaction                 1.014 (0.576--1.786)    0.962                         1.078 (0.602--1.933)    0.800
  rs12543663 (CC+AC vs. AA)   1.024 (0.661--1.588)    0.915                         1.006 (0.639--1.583)    0.979
  Smoking exposure            7.586 (5.017--11.471)   0.000                         6.626 (4.337--10.123)   0.000
  Interaction                 1.082 (0.501--2.337)    0.842                         1.147 (0.518--2.541)    0.735
  rs710886 (TT vs. CC+CT)     1.290 (0.894--1.862)    0.174                         1.343 (0.923--1.956)    0.123
  Smoking exposure            7.897 (5.099--12.232)   0.000                         6.754 (4.306--10.596)   0.000
  Interaction                 0.950 (0.519--1.738)    0.868                         1.060 (0.570--1.970)    0.854
  rs16901904 (CC+CT vs. TT)   1.085 (0.770--1.530)    0.640                         1.104 (0.776--1.570)    0.584
  Smoking exposure            7.221 (4.619--11.287)   0.000                         6.218 (3.924--9.853)    0.000
  Interaction                 1.208 (0.682--2.138)    0.517                         1.286 (0.713--2.322)    0.403

OR adjusted by age and gender.

*p* adjusted by age and gender.

Discussion {#s010}
==========

Lung cancer is an extremely complicated malignant tumor with multiple etiologies. As we all know, smoke is not able to explain the full causes of lung cancer. Treating lung cancer patients better and more effectively is critical to identify other early diagnostic biomarkers. LncRNAs are usually classified as follows: sense, antisense, bidirectional, intronic, and intergenic (Xu *et al.*, [@B32]). Through transcriptome sequencing and microarrays analysis, multiple lncRNAs are found to be associated with susceptibility to lung cancer and its subtype (Wang *et al.*, [@B28]; White *et al.*, [@B31]; Xu *et al.*, [@B32]).

LncRNA-*PCAT1* was first identified as a biomarker for prostate cancer by transcriptome sequencing and it was also named accordingly (Prensner *et al.*, [@B21]). Previous studies have shown that lncRNA-*PCAT1* plays key roles in many diseases by distinct mechanisms. A study from Zhang *et al.* ([@B38]) showed that lncRNA-*PCAT1* affects extrahepatic cholangiocarcinoma (ECC) progression by the Wnt/β-catenin-signaling pathway and *PCAT1* may be a potential therapeutic target for ECC treatment. Another study showed that lncRNA-*PCAT1* contributes to prostate cancer risk by regulating FSCN1 via miR-145-5p (Xu *et al.*, [@B33]). Zhao *et al.* ([@B40]) showed that lncRNA-*PCAT1* was correlated with cell proliferation, migration, and invasion of nonsmall cell lung cancer cells, which suggested a novel therapeutic target of lung cancer. The study from Li *et al.* ([@B16]) suggested that lncRNA-*PCAT1* might influence the development of nonsmall cell lung cancer via the miR-149-59/LRIG2 axis.

Previous studies showed that there were a majority of GWAS or trait-associated loci in the 8q24 gene desert region, a well-known genetic region (Huppi *et al.*, [@B14]; Panagiotou *et al.*, [@B19]). LncRNA-*PCAT1* is located at chromosome 8q24.21. Yuan *et al.* ([@B36]) showed that rs1902432 polymorphisms in lncRNA-*PCAT1* had a significant association with prostate cancer risk in the additive model, co-dominant model, and recessive model. A study from Lin *et al.* ([@B17]) suggested that rs710886 (A\>G), an eQTL for lncRNA-*PCAT1*, significantly reduced bladder cancer risk (OR = 0.86, *p* = 0.046).

This case--control study recruited 468 lung cancer cases and 561 cancer-free controls, which were matched in age and gender between the case and control groups. Through this research, we found that polymorphisms in lncRNA-*PCAT1* had a significant association with lung cancer risk. Rs1902432 was in high linkage disequilibrium (*r*^2^ = 0.99) with rs1026411, based on HaploReg v4.1 (Ward and Kellis, [@B29]). In our study, genetic variants in rs1026411 may be protective factors in non-small cell lung cancer, which is different from rs1902432 in prostate cancer. The possible reason is that pathogenic mechanisms were different in distinct cancers. The analysis results of HaploReg database (Ward and Kellis, [@B29]) also showed that rs710886 is an eQTL for *PCAT1* and is located at a region that overlaps with enhancer histone marks in two tissues. Our results indicated that rs710886 polymorphisms were significantly associated with reduced risk of non-small cell lung cancer. The results were consistent with those in bladder cancer. Besides, we also found some statistically significant association in the subtype of lung adenocarcinoma and squamous cell carcinoma. Although rs16901904 polymorphisms had no statistically significant association with the risk of lung cancer, non-small cell lung cancer, and lung adenocarcinoma, we find that rs16901904 polymorphisms were associated with the risk of lung squamous cell carcinoma. The reason might be that the result was a false positive, which was caused by a smaller sample size after stratification.

All study subjects included in this study were based on a set of strict inclusion and exclusion criteria. By selecting newly diagnosed patients to the case group, this study effectively avoids Neyman bias, which frequently occurs in case--control studies. The control group was matched to the case group in age and gender. All unconditional logistic regression analyses were adjusted by age, gender, and smoking status; by this means, confounding bias can be reduced effectively. However, there were still some limitations in this study. First, there may be Berkson\'s bias in this study, since all study subjects were selected from the hospital. Second, all controls were selected from the medical examination center of hospitals, which could not represent the whole control population to some extent. Third, there was a lack of further functional studies to confirm our results.

Conclusion {#s011}
==========

Genetic variants in lncRNA-*PCAT1* may be associated with lung cancer susceptibility in a northeastern Chinese population. The interaction between lncRNA-*PCAT1* and smoking status does not exist in this study.
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